TIBURIO THERAPEUTICS
Tiburio Therapeutics is a developer of drug compounds intended to treat tumors and endocrine diseases.The company's compounds aid in the treatment of non-functioning pituitary adenoma using a dopamine-somatostatin chimeric molecule that has the potential to shrink or halt tumor growth, providing patients with effective treatment for rare neuroendocrine tumors and endocrine diseases.
TIBURIO THERAPEUTICS
Industry:
Biotechnology Health Care Medical Pharmaceutical
Founded:
2018-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.tiburio.com
Total Employee:
1+
Status:
Active
Contact:
+1 (617) 231-6050
Total Funding:
31 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Apple Mobile Web Clips Icon Google Tag Manager Google Analytics LetsEncrypt Amazon SSL By Default Organization Schema Google Universal Analytics
Similar Organizations
Amylyx Pharmaceuticals
Amylyx Pharmaceuticals specializes in providing solutions for Alzheimer’s and other diseases of the brain.
Dyne Therapeutics
Dyne Therapeutics is a developer of targeted therapies intended for serious muscle diseases.
Engrail Therapeutics
Engrail Therapeutics is a developer of medicines to transform the lives of patients with life-limiting diseases of the nervous system.
Entrada Therapeutics
Entrada Therapeutics is a developer of novel therapeutics intended to treat devastating diseases.
Esperion
Esperion discovers and develops pharmaceutical products for the treatment of cardiovascular and metabolic diseases.
Neurogene
Neurogene is a developer of genetic medicines intended to improve patient outcomes for neurological disorders.
NimbleRx
Nimble provides a pharmacy experience centered around the patient's needs to provide a more streamlined workflow.
Obsidian Therapeutics
Obsidian Therapeutics is a developer of a next-generation cell and gene therapies created to extend adoptive immunotherapy.
ROME Therapeutics
ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome.
Vico Therapeutics
Vico Therapeutics is a developer of ribonucleic acid (RNA) modulating therapies.
Current Employees Featured
Michael Culler Scientific Founder and Chairman, Scientific Advisory Board @ Tiburio Therapeutics
Scientific Founder and Chairman, Scientific Advisory Board
Founder
Investors List
Lundbeckfonden Ventures
Lundbeckfonden Ventures investment in Series A - Tiburio Therapeutics
New Enterprise Associates
New Enterprise Associates investment in Series A - Tiburio Therapeutics
Alexandria Venture Investments
Alexandria Venture Investments investment in Series A - Tiburio Therapeutics
Longitude Capital
Longitude Capital investment in Series A - Tiburio Therapeutics
Official Site Inspections
http://www.tiburio.com
- Host name: a904c694c05102f30.awsglobalaccelerator.com
- IP address: 76.223.54.146
- Location: Seattle United States
- Latitude: 47.54
- Longitude: -122.3032
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98108
More informations about "Tiburio Therapeutics"
Tiburio Therapeutics - Crunchbase Company Profile & Funding
Tiburio Therapeutics is a developer of drug compounds intended to treat tumors and endocrine diseases.The company's compounds aid in the treatment of non-functioning pituitary adenoma …See details»
Tiburio Therapeutics Inc. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Tiburio Therapeutics Inc. of Cambridge, MA. Get the latest business insights from Dun & Bradstreet.See details»
Tiburio Therapeutics Company Profile 2024: Valuation, Funding ...
Tiburio Therapeutics General Information Description. Provider of novel treatments designed to treat rare neuroendocrine tumors and rare endocrine diseases. The company's clinical stage …See details»
Tiburio Therapeutics - Contacts, Employees, Board Members, …
Tiburio Therapeutics has 1 current employee profile, Scientific Founder and Chairman, Scientific Advisory Board Michael Culler. Michael Culler Scientific Founder and Chairman, Scientific …See details»
Tiburio Therapeutics - VentureRadar
Tiburio is a clinical stage biopharmaceutical company dedicated to advancing novel treatments for rare neuroendocrine tumors and rare endocrine diseases where there is significant patient …See details»
Tiburio Therapeutics Inc - Company Profile and News
Company profile page for Tiburio Therapeutics Inc including stock price, company news, executives, board members, and contact informationSee details»
Tiburio Therapeutics - Craft
Tiburio Therapeutics is a biopharmaceutical company, which is dedicated to advancing novel treatments for rare neuroendocrine tumors and rare endocrine diseases. The Company's …See details»
Tiburio Therapeutics - Funding, Financials, Valuation & Investors
Tiburio Therapeutics is a developer of drug compounds intended to treat tumors and endocrine diseases. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. ... How much …See details»
Tiburio Therapeutics CEO and Key Executive Team | Craft.co
Tiburio Therapeutics's Director is Chris Adams. Other executives include Sandip K. Agarwala, Director; Michael D. Culler, Scientific Founder and Chairman, Scientific Advisory Board and 4 …See details»
Cydan Announces Formation of Tiburio Therapeutics Inc. to …
Jan 4, 2019 Tiburio is a clinical stage biopharmaceutical company dedicated to advancing novel treatments for rare neuroendocrine tumors and rare endocrine diseases where there is …See details»
Tiburio launches with $31M and clinical-stage drugs for rare …
Jan 3, 2019 Tiburio will start phase 2-enabling studies for TBR-760 immediately and planning to start a phase 2 trial in NFPA patients in the second half of 2019. The series A, drawn from …See details»
Tiburio Therapeutics | Lundbeckfonden
Tiburio Therapeutics is a drug development company that develops novel small molecule treatments for potentially life-threatening rare neuroendocrine tumours and endocrine diseases …See details»
Tiburio Therapeutics - The Lundbeck Foundation
Tiburio Therapeutics is a drug development company that develops novel small molecule treatments for potentially life-threatening rare neuroendocrine tumours and endocrine diseases …See details»
Tiburio Therapeutics | CipherBio
Explore Tiburio Therapeutics's investment information, scientific platforms, therapeutic approaches, indications and more here!See details»
Tiburio Therapeutics: A Map for Selling to this Stealth Biotech …
Oct 21, 2020 Heather Halem, Ph.D. - Vice President, Research of Tiburio Therapeutics, Heather brings more than 17 years of pharmaceutical experience to Tiburio with strong expertise in …See details»
Cydan Announces Formation of Tiburio Therapeutics Inc. to …
Jan 3, 2019 Tiburio is a clinical stage biopharmaceutical company dedicated to advancing novel treatments for rare neuroendocrine tumors and rare endocrine diseases where there is …See details»
Tiburio Therapeutics | Biotechnology - The Pharmaletter
Tiburio is a privately-held biopharma focused on developing treatments for rare neuroendocrine tumors and rare endocrine diseases. It is the third company to be launched by the USA-based …See details»
Developing Transformative Treatments for Rare Endocrine Diseases
Jul 1, 2020 Tiburio is actively taking TBR-760 to the IND phase and expects to initiate a phase II clinical trial in patients with NFPA in the second half of 2020. Targeting Rare Endocrine …See details»
Tiburio: Investing in Traditional Drug Development in the Era of …
Jan 3, 2019 Third, an excellent CEO has joined Tiburio – Abraham Ceesay, who has 17 years of experience leading biopharmaceutical companies and was most recently Chief Operating …See details»
Tiburio Announces Publication of Preclinical TBR-760 Data
May 11, 2020 Tiburio is dedicated to developing transformative treatments for rare endocrine diseases. The company is advancing a unique class of chimeric compounds that has the …See details»